The data, published online in the journal Cell Reports, demonstrate that intravenous administration of an mRNA therapeutic encoding for human methylmalonyl-CoA mutase, the enzyme most frequently mutated in MMA, enabled liver expression of MUT in MMA mouse models, leading to a significant reduction in methylmalonic acid, a substantial improvement in weight gain, and the complete survival of the full cohort of treated mice versus control group.
Repeat IV dosing did not increase markers of liver toxicity or inflammation.
The study was conducted in partnership with researchers in the Medical Genomics and Metabolic Genetics Branch of the National Human Genome Research Institute at the National Institutes of Health. Both Moderna and NIH researchers conducted research for the study.
MMA, is a rare, autosomal recessive organic acidemia/aciduria, most commonly caused by a deficiency of the enzyme methylmalonic CoA mutase, due to a defective or missing MUT protein. It is primarily a pediatric disease with onset in early infancy and associated with significant mortality and morbidity. Currently, liver and/or kidney transplant is the only effective treatment.
Moderna is developing an mRNA therapeutic, mRNA-3704, which directs cells in the liver to produce and express a functional MUT enzyme, restoring the metabolic pathway and reducing toxic acid build-up.
Privately held Moderna is developing mRNA vaccines and therapeutics as a new class of medicines for infectious diseases, cancer (immuno-oncology), rare liver diseases, cardiovascular and pulmonary diseases, through proprietary development and collaborations with strategic partners.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine